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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma is the most common head and neck malignancy in Indonesia. 
Diagnosis errors often occur in nasopharyngeal carcinoma due to non-specific symptoms such as symptoms of 
an infectious disease that resemble the symptoms of nasopharyngeal carcinoma. 
Case Report: In this case, it was explained how this diagnostic error occurred. A man, 39 years old with major 
complaints of right and left neck lumps, the patient initially came to an ear nose throat (ENT) specialist and 
performed fine needle aspiration (FNA) and suggested a biopsy. But the patient did not continue his treatment 
with ENT doctor. The patient continued his treatment at pulmonologist and was diagnosed with glandular 
Tuberculosis (TB) and received TB treatment. In the following 4th month on TB treatment, the lump in the right 
and left neck was felt bigger, then the pulmonary expert refers the patient to an oncology surgeon, afterwards 
the oncology surgeon department refers to ENT specialist due to the suspicion towards nasopharyngeal 
carcinoma. In the ENT department biopsy was performed on the nasopharynx and the result is bilateral 
nasopharyngeal Non-Keratinizing Cell Carcinoma, undifferentiated (WHO type III). 
Conclusion: The patient was diagnosed with stage IV B nasopharyngeal carcinoma (T1N3M0). Currently, the 
patient has undergone 3 cycle of chemotherapy with paclitaxel and cisplatin regimen. 
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1. CASE REPORT 
Nasopharyngeal carcinoma is one of the most common tumor, with an 
incidence of 0.29 per 100,000 population. The highest incidence is in China, 
South Asia and North Africa [1]. While the cause of NPC is multifactorial, 
it is associated with an interaction between the chronic infection of the 
oncogenic gamma herpes virus Epstein-Barr virus in which the Epstein-Barr 
virus has infected more than 95% of the world's population. Besides 
environmental factors and genetic factors, it is also involved in carcinogenic 
multistep processes [2]. WHO divides nasopharyngeal carcinoma pathology 
into three histological types consisting of keratinizing squamous cell 
carcinoma, non-keratinizing carcinoma, which is divided into differentiated 
and undifferentiated subtypes. Undifferentiated non-keratinizing NPC is the 
most frequent and strong type associated with EBV (Epstein-Barr Virus) [3-
5]. Nasopharyngeal carcinoma often occurs in the lateral wall of the 
nasopharynx, especially in the Rosenmuller fossa, but it can also occur in 
the superior and posterior walls. Most of the patient's main complaints are 
the presence of a lump in the neck accompanied by other symptoms in the 
nose such as epistaxis, nasal obstruction, blood stained rhinorrhea. In the 
ear, clinical features that often occur are tinnitus and serous otitis media due 
to blockage of the eustachian tube, another common complaint is cephalgia, 
a cranial nerve disorder that usually occurs with an intracranial spread that 
occurs in the advanced stage [1]. 
A man, 39 years old admitted to RSWS ENT outpatient clinic with 
major complaints of lumps in the right and left neck since three years 
ago, initially the lumps appeared as big as marble, lumps settled and 
enlarged since one year ago, epistaxis history exists, history of blood-
stained rhinorrhea exists, cephalgia exists, tinnitus since one year 
ago, otalgia was present. The patient had been carried out FNA in the 
neck one year ago which was recommended by an ENT specialist. The 
result was Colli dextra: suspicious a malignant epithelial tumor 
metastasis (differential diagnosis: inflammation granulomatous) in 
Colli dextra, and granulomatous caused by TB inflammation can be 
considered in Colli sinistra. After underwent FNA examination, 
patient did not continue the examination to the ENT specialist, patient 
was continued treatment to a pulmonologist with complaints of 
coughing up blood, in the lung part X-ray thorax and sputum was 
done, but the result was within normal limit, then from the treatment 
in the lung part the patient is diagnosed with glandular TB and advised 
to take anti-tuberculosis drug for 6 months. In the following 4th 
month of treatment, the lump in the neck was felt to be enlarged and 
pulmonologist referred patients to oncology surgeon, from oncology 
surgeon got suspicion towards the nasopharyngeal tumor afterwards 
they referred the patient to an ENT specialist. 
From the physical examination of anterior rhinoscopy, the normal 
mucosa was obtained, the surface was smooth and not hyperemic, 
normal concha, the septal deviation was to the right, the phenomenon 
of the palatum molle was negative on the right and left side. On 
otoscopy and pharyngoscopy, the result was within normal limit. In 
the neck region examination, bilateral and multiple lymph nodes 
enlargements in the submandibular region with a size of 11x8x2cm, 
submental dextra size 4.5x3x1.5 cm, internal submandibular 
approximate 8x7x2 cm, deep inferior jugular 4x3x1.5 cm size. The 
CT scan examination of the coronal view of nasopharyngeal was then 
performed with the impression of bilateral nasopharyngeal mass 
suspicion, suspected right cervical lymphadenopathy, multi sinusitis, 
atrophycans rhinitis and nasal septal deviation (figure 1). Then it was 
decided to do a nasopharyngeal biopsy via endoscopy. On endoscopy 
examination, there was mass in nasopharynx the dextra and sinistra 
nasopharynx with uneven surface, hyperemic, and bleed easily. Then 
we performed a biopsy of the nasopharyngeal tumor. The results of 
the biopsy are bilateral nasopharyngeal Non-keratinizing Cell 
Carcinoma, Undifferentiated (WHO type III).  
The examination was followed by an examination of the thoracal 
rontgent, abdominal ultrasound and bone survey and no signs of 
metastasis were found on the three examinations. The conclusion was 
that the patient was diagnosed with stage IV B nasopharyngeal 
carcinoma (T1N3M0) and decided to administer chemotherapy with 
paclitaxel and cisplatin regimens. Currently, the patient has 
underwent the third cycle of chemotherapy. 
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Picture 1. CT scan of the nasopharynx (coronal view) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 2. Photos of patients before chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Picture 3. Photos of patients after underent the third cycle of 
chemotherapy 
2. DISCUSSION 
The most common complaint in nasopharyngeal carcinoma is 
cervical lymphadenopathy, which is followed by complaints of nasal 
obstruction, epistaxis, and serous otitis media [6, 7]. Approximately 
70% of nasopharyngeal carcinoma patients initially came to a doctor 
with major complaint of the neck mass, and 60 to 96% of 
nasopharyngeal carcinoma patients show cervical lymph node 
adenopathy [2, 6].  Tuberculosis (TB) has remained one of the world's 
deadliest communicable diseases. It can affect the lung (pulmonary TB) 
and other sites (extrapulmonary TB) as well. According to the WHO 
2014, 6.1 million cases of TB were reported with 5.7 million newly 
diagnosed cases and 0.4 million previously diagnosed cases [6, 8]. In 
new cases, 0.8 million patients had extrapulmonary TB. Head and neck 
regions can be present in up to 10% of all TB cases with cervical lymph 
nodes most commonly involved [9]. In this case report, patients with 
early complaints of lumps in the right and left neck, which is one 
symptom that often occurs in nasopharyngeal carcinoma and specific 
infection. In this case, the symptoms of nasopharyngeal carcinoma were 
disguised due to complaints of coughing up blood which is one of the 
symptoms of the infection process and was supported by FNA results 
that leads to tuberculosis infection. Some studies state that there are 
three factors that cause the misdiagnosis of NPC, which are patient 
factors (patient delay), facilities and infrastructures at health facilities, 
and the doctor [2, 10]. 
Nasopharyngeal carcinoma is the most malignant tumor found 
among malignant ENT tumors in Indonesia, where nasopharyngeal 
carcinoma is included in the top five malignant tumors with the highest 
frequency, whereas in the head and neck area occupies the first place 
[6, 10, 11]. 
Early detection of NPC is difficult, but early diagnosis is important 
to achieve optimum results of treatment [12, 13], in this case when the 
patient first develops a lump in the neck, the FNA results have shown 
signs of suspicion towards nasopharyngeal carcinoma, but the patient 
does not continue treatment at ENT. For this reason, it is very important 
for a doctor to be more careful in diagnosing a disease, especially if 
from the examination of anatomical pathology to the two diagnoses, it 
is better to do an additional investigation before establishing a diagnosis 
and doing therapy [14]. 
Before the patient underwent treatment for glandular TB, a lump in 
the neck of the patient with a size of <6 cm. When this patient came to 
RSWS ENT outpatient clinic with a size of a lump in the neck> 6 cm 
after 4 months of anti-tuberculosis drug administration, the patient has 
concluded with stage IVB nasopharyngeal carcinoma (T1N3M0). 
Patients in early-stage NPC (T1, T2, N0-1 without metastasis) have 5 
years survival rate of 85%, while in advanced stage (T3, T4, and N2, 
N3 without metastasis) the 5 years survival rate is 65%. 5.8 The 10 years 
free disease rate in the early stage is 67-71% and for the advanced stage, 
it is 29-54%. Therefore, it is important to recognize factors related to 
the delay of symptoms and misdiagnosis to improve identification and 
early management [2, 6, 15]. 
3. CONCLUSION 
Early detection of nasopharyngeal carcinoma is quite difficult due 
to non-specific symptoms that cause diagnostic errors when the patient 
comes to the hospital for the first time. In establishing a diagnosis of 
nasopharyngeal carcinoma it is very important to pay attention to every 
symptom and sign that is present in the patient, symptoms that are 
similar between several diseases require additional checks that must be 
done to establish a definite diagnosis. Therefore the need to improve 
patient knowledge in recognizing symptoms of malignancy and 
awareness to check their health to the right expert doctor and to increase 
the knowledge of health workers in performing history taking, physical 
examination and more complete investigation to establish a diagnosis 
of nasopharyngeal carcinoma to avoid misdiagnosis which can have an 
impact on the patient's survival rate. 
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